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94cally linked to neuroinflammation and surrounded by inflammatory cells such as microglia and infil-
trating immune cells. Here, we describe nonneurogenic doublecortin (DCX) positive cells, DCX
being generally used as a marker for young immature neurons, at sites of amyloid-b plaques in various
transgenic amyloid mouse models and in human brains with plaque pathology. The plaque-associated
DCX1 cells were not of neurogenic identity, instead most of them showed coexpression with markers
for microglia (Iba1) and for phagocytosis (CD68 and TREM2). Another subpopulation of plaque-
associated DCX1 cells was negative for Iba1 but was highly positive for the pan-leukocyte marker
CD45. These hematopoietic cells were identified as CD3-and CD8-positive and CD4-negative T-cells.
Peculiarly, the DCX1/Iba11 microglia and DCX1/CD81 T-cells were closely attached, suggesting
that these two cell types are tightly interacting and that this interaction might shape plaque pathology.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).95
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1081. Introduction
Alzheimer’s disease (AD) is characterized by a progres-
sive loss of cognitive functions [1,2]. Formation of
neurofibrillary tangles (NFTs) and amyloid-b plaques is
described as major neuropathological hallmarks of AD,
and several transgenic mouse models are designed to: The authors declare that there is no conflict of interest.
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109produce amyloid-b plaques and/or tau pathologies and to
mimic the cognitive deficits of AD for studying AD
pathogenesis [3,4]. Neuroinflammation, especially the
activation of microglia is heavily debated to contribute to
disease progression and to worsen late-stage pathology
[5–7]. Microglia cells are located directly at sites of
amyloid deposits in AD brains, where they are supposed to
phagocytose the amyloid plaque material [8,9]. Several
reports suggest that in more advanced stages of plaque
pathology and AD, microglia become increasingly
dysfunctional in phagocytosis, in cell proliferation,
motility, signaling, and in proteostasis, all contributing toimer’s Association. This is an open access article under the CC BY-NC-ND
 6 April 2018  6:19 pm  ce
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225an altered microglia phenotype [10]. The occurrence of pe-
ripheral immune cells in the brain, specifically T-cells, and
their functional role and interaction with brain resident glial
cells is currently discussed. For example, there is evidence
for increased T-cell homing into the aged but otherwise
healthy brain [11, 12]. Moreover, higher T-cell numbers
are found in the brains of several amyloid plaque mouse
models [13]. However, the specific T-cell subtypes, their
functional relevance, and a possible modulatory activity of
T-cells in brains with plaque pathology are still controver-
sial [14].
Besides neuroinflammation, altered levels of adult neuro-
genesis are reported to manifest along AD pathology in
several amyloid-b transgenic mouse models [15]. Adult hip-
pocampal neurogenesis is the production of new functional
neurons from neural stem and progenitor cells and takes
place in specific neurogenic niches in the mammalian brain,
namely the subgranular zone of the dentate gyrus and the
subventricular zone of the lateral ventricle walls [16–19].
There, stem cells give rise to neuronal progenitor cells,
which mature and integrate functionally in the existing
neuronal network [20]. The population of neuronal precur-
sors or young immature neurons can be identified by its
expression of the microtubule-associated protein doublecor-
tin (DCX) [21,22].
We recently demonstrated changes in hippocampal neu-
rogenesis already at very early stages of disease pathology
in transgenic amyloid-b animal models, before the manifes-
tation of amyloid-b plaques [23]. In the frame of this
analysis, we made the surprising finding of DCX-
immunoreactive cells outside the neurogenic niche at sites
of amyloid deposits. Here, we present a detailed analysis
of the identity of DCX-immunoreactive cell populations
associated with amyloid plaques in cortical and hippocam-
pal brain regions of various transgenic amyloid mouse
models and in human brains with plaque pathology and in
AD specimen. We report for the very first time on DCX-
immunoreactive microglia in amyloid mouse models and
on DCX-positive T-cells that presumably infiltrate the brain
parenchyma of AD transgenic mice and tightly associated
with the resident microglia.226
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2432. Material and methods
2.1. Animals
Female amyloid-b precursor protein (APP) Swedish
PS1 dE9 (APP-PS1) mice [24] expressing a chimeric mouse
or human mutant amyloid precursor protein (Mo/
HuAPP695swe) and a mutant human presenilin 1 (PS1
dE9) both directed to CNS neurons under the prion protein
promoter (Jackson Laboratory, http://www.jax.org/strain/
005864) were used. For brain histology, we analyzed mice
at 3, 10, and 13 months of age. Age-matched nontransgenics
derived from the breeding of APP Swedish PS1 dE9 were
used as control animals. Mice were housed at the UniversityFLA 5.5.0 DTD  JALZ2591_proofHospital Bonn–Clinical Neuroscience in groups under stan-
dard conditions at a temperature of 22C and a 12 h light or
dark cycle with ad libitum access to standard food and water.
Animal care and handling were performed according to the
Declaration of Helsinki and approved by local ethical com-
mittees. Brain sections of the APP-Lon/Swe mice overex-
pressing hAbPP751 with the London (V717I) and Swedish
(K670M/N671L) mutations [25,26] and the transgenic
APP-SDI mouse model overexpressing human amyloid-b
precursor protein (APP 770 isoform) with the Swedish
K670N/M671L, Dutch E693Q, and Iowa D694 N mutations
[27,28] were kindly provided by Prof. Christian Humpel
(Laboratory of Psychiatry and Experimental Alzheimer’s
Research, Department of Psychiatry Psychotherapy and
Psychosomatik, Medical University of Innsbruck, Austria).
Brain sections from transgenic Tg2576 mice [29,30]
overexpressing the human APP Swedish mutation and
wild type littermates at postnatal ages from 3 to 18 months
were kindly provided by Prof. Steffen R€oßner (Paul
Flechsig Institute for Brain Research, University of
Leipzig, Germany). Brain sections from DCX knockout
mice (DCX-KO) and age-matched controls [31] were kindly
provided by Fiona Francis (Institut du Fer a Moulin, Paris,
France). Brain sections of 8-month-old human a-synuclein
overexpressing mice (D-line), a model of synucleinopathy
and of Lewy body dementia [32–34], were included in the
study.2.2. Behavior test
For analysis of spatial learning and memory function,
Morris water maze (MWM) test was performed in accor-
dance with the local Animal Health Commission
(BMWFW-66.019/0032-WF/V/3 b/2016). This MWM para-
digm was performed as previously published [35]. For
behavior analysis, 13- to 15-month-old female and male
APP-PS1 and age-matched Nestin-CreERT2/R26R-YFP
control animals [35,36] were used (n 5 4/group). For
the MWM test, a 108 cm round basin arena filled with
22 6 1C warm water was used. A 10 ! 10 cm square
platform was placed 1 cm below the water surface in the
maze. Big black cue symbols were put on each wall of the
basin and the testing room to allow the animals spatial
orientation. The experimental setup was not changed
throughout the whole learning session and performed
under constant light conditions. Water maze trials
(maximum 60 s) for learning were performed twice a day
for a total of 5 days. On each trial, every mouse was put in
the water and given 60 s to swim and locate the
submerged platform. If the platform was not detected
within 60 s, the animal was guided onto the platform and
allowed to remain there for 10 s to learn the spatial
position of the platform. Only on the first trial of day 1,
the platform was marked with a black flag to visualize the
platform location to the mice. On day 6, an additional
memory paradigm was performed by removing the 6 April 2018  6:19 pm  ce
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317platform, and mice were tracked for 60 s. The swim path,
that is, the total distance moved and the swim speed was
recorded using EthoVision software (XT 9.0.726, Noldus).
In the absence of the platform during the last session, the
time the animals spent in the platform quadrant and the
visits in the platform quadrant were additionally calculated.8
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3522.3. Human brain samples
We used 7 mm hippocampal sections from formalin-
fixed paraffin-embedded brain samples which were ob-
tained from the Newcastle Brain Tissue Resource in accor-
dance with Newcastle University ethics board and ethical
approval awarded by the Joint Ethics Committee of New-
castle and North Tyneside Health Authority (reference:
08/H0906/136).
Irrespective of clinical diagnoses, all brains underwent
neuropathological examination according to a routine proto-
col that uses standardized neuropathological scoring or
grading systems, including NFT Braak staging [37,38],
Consortium to Establish a Registry for Alzheimer’s
Disease scores [39], Newcastle/McKeith Criteria for Lewy
body disease [40], National Institute on Aging—Alz-
heimer’s Association guidelines [41], and Thal phases of
amyloid-b deposition [42]. Our study group consisted of
14 AD cases which showed NFT Braak stages 4-6 and ful-
filled the criteria for high AD neuropathological change ac-
cording to the National Institute on Aging–Alzheimer’s
Association guidelines [41] and besides classical AD pathol-
ogy (i.e., NFTs, amyloid plaques, and neuritic plaques) did
not show any other pathology (e.g., Lewy bodies, TDP-43
positive intracellular inclusions) in the hippocampus. As
controls, we used seven cases with NFT Braak stages 0 to
3, which showed no or only very limited amounts of amyloid
pathology in the hippocampus.353
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3662.4. Perfusion and tissue processing
APP-PS1 animals were anesthetized and transcardially
perfused for immunohistochemistry as previously described
[43]. Following perfusion, the brains were extracted and
postfixed in 4% paraformaldehyde, sodium phosphate
buffer solution (PBS, 0.1 M; pH 5 7.4) over night at
4C. The brains were cryoprotected and transferred into
30% sucrose in 0.1 M sodium PBS (pH 5 7.4). Sagittal
sections of 40 mm were cut on dry ice with a sliding
microtome.9
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3772.5. Immunohistochemistry
Fluorescence immunohistochemistry of mouse tissue was
performed on free-floating sections as previously described
[23,43]. Antigen retrieval was performed depending on the
used primary antibody by steaming the sections for
15–20 min in citrate buffer (pH 5 6.0, Sigma). The
following primary antibodies were used:FLA 5.5.0 DTD  JALZ2591_proofRabbit anti-DCX (1:300, Cell Signaling), normal rabbit
IgG control (prediluted to the concentration of rabbit anti-
DCX c 5 156 mg/mL and finally used at 1:300, Cell
Signaling), goat anti-Iba1 (1:500, Abcam), rat anti-CD45
(1:100, Millipore), mouse anti-Ab (1:1000, Covance), sheep
anti-TREM2 (1:300, R&D Systems), rat anti-CD68 (1:250,
Serotec), rat anti-CD3 (1:100, Bio-Rad), rat anti-CD8
(1:100, eBioscience), goat anti-PCNA (1:300, Santa Cruz
Biotechnology), mouse anti-Nestin (1:300, Abcam), goat
anti-Sox2 (1:1000, Santa Cruz Biotechnology), mouse
anti-PSA-NCAM (1:2000, Millipore), chicken anti-GFAP
(1:2000, Abcam), goat anti-Olig2 (1:300, R&D Systems),
mouse anti-NeuN (1:500, Millipore), rat anti-B220 (1:100,
eBioscience), rat anti-Ly6G (1:100, eBioscience), rat anti-
CD169 (1:50, Bio-Rad), rat anti-CD4 (1:100, eBioscience),
and rat anti-Foxp3 (1:100, eBioscience). For a synuclein
staining rat anti-a-synuclein (1:50, Enzo) antibody was
used and antibody incubation time was increased for a total
of 2 days.
Sections were extensively washed in PBS and incu-
bated for 3 h at RT Qin secondary antibodies all diluted
1:1000. The following secondary antibodies were used:
donkey anti-rabbit Alexa Fluor 568 or Alexa Fluor 647,
donkey anti-goat Alexa Fluor 568, donkey anti-rat Alexa
Fluor 488 or Alexa Fluor 568, donkey anti-sheep 488,
donkey anti-mouse Alexa Fluor 568 (all Invitrogen or Mo-
lecular Probes), donkey anti-rat Rhodamine Red, donkey
anti-mouse AF647, donkey anti-goat AF647, donkey
anti-chicken Alexa Fluor 647, donkey anti-rat AF647
(all Jackson ImmunoResearch). Nucleus counterstaining
was performed with 40,60-diamidino-2-phenylindole dihy-
drochloride hydrate (DAPI 1 mg/mL, 1:2000, Sigma).
For qualitative amyloid-b plaque staining, Thioflavin S
(1 mg/mL, 1:625, Sigma) was added to the secondary
antibody solution. Tissue sections from AD brains were
additionally treated with 0.2% Sudan Black (Sigma) in
70% ethanol for 1–2 minutes to reduce the autofluores-
cence in tissue from old animals [44]. After this treatment,
the sections were extensively washed in PBS and mounted
onto microscope glass slides (Superfrost Plus, Thermo
Scientific). Brain sections were cover slipped semi-dry
in ProLong Gold Antifade Mountant (Life Technologies)
or Fluorescence Mounting Medium (Dako).
Human samples were immunohistologically stained as
follows: after antigen retrieval and H2O2 quench, sections
were incubated in a primary antibody for 1 hour at room tem-
perature. The following primary antibody was used: rabbit
anti-DCX (1:3000, Abcam). Visualization was performed
using the Menarini Diagnostics X-Cell DAB kit (MP-
XCPDAB-U100) following the outlined protocol. All
washes were done in TBS Qbuffer pH 7.6.2.6. Microscopy, visualization, and image processing
For qualitative and quantitative microscopic analysis
of mouse tissue, confocal laser scanning microscopy was 6 April 2018  6:19 pm  ce
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460performed using a LSM 700 and LSM 710 from Zeiss.
Representative images were taken as z-stack image from
the stained sections. Orthogonal projections (maximum in-
tensity) of the images were created and depicted in respec-
tive false colors using Zen 2012 blue edition software. For
3D reconstruction, images were processed at the LSM 710
using the Zen 2011 SP7 (black) software. Images were
generated using the 3D tool with surface representation
function, and each staining was depicted in respective
false colors. Representative images of human DCX-
stained samples were taken using a Nikon Eclipse E600
microscope and the NTS Elements Imaging Software
(version 4.30.01).14
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5112.7. Western blot analysis
For protein analysis, brains from 13-month-old APP-PS1
and littermates (n5 4/group) were extracted, and the hippo-
campus and cortex were dissected from one hemisphere per
animal. Cortex and hippocampus regions were immediately
frozen on dry ice and stored for further processing at280C.
Brain regions were homogenized using an electric homoge-
nizer pestle in 500 mL RIPA buffer (50 mM Tris-HCl pH 7.4,
1% NP-40 [Sigma], 0.25% Na-deoxycholate [Sigma], and
150 mM NaCl, 1 mM EDTA), and protease (cOmplete,
Roche) and phosphatase inhibitors (PhosStop, Roche). Af-
terward, lysates were manually dissociated using surgical
needles of 20G and 27G size (Dispomed) to obtain a homo-
geneous sample solution. Samples were thoroughly vor-
texed, placed on an orbital shaker at 4C for 30–60 min,
and were then centrifuged for 20 min at 14,000 g. Superna-
tants were collected, and protein concentrations were calcu-
lated using Pierce BCA Protein Kit (ThermoFisher
Scientific) following manufacturer’s instruction. Total pro-
tein (7.5 mg) was denaturated for 5 min at 98C in RIPA
buffer with SDS sample loading buffer and loaded onto a
Mini-Protean TGX stain-free precast gel (Bio-Rad). After
standard SDS-polyacrylamide gel electrophoresis, proteins
were blotted onto a Mini-Format 0.2 mm nitrocellulose
membrane using the Trans-Blot Turbo System (Bio-Rad) ac-
cording to manufacturer’s instructions. Afterward, the mem-
branes were washed in TBS-T (TBS with 0.1% Tween) for a
total of three washes. Membranes were blocked for 1 h at RT
with TBS-T containing 4%BSA (Sigma) and incubated over
night at 4C with following primary antibodies: rabbit anti-
DCX (1:1000, Cell Signaling) and mouse anti-b-actin
(1:2000, Sigma). The next day, membranes were washed
three times 10 min in TBS-T and incubated with following
secondary antibodies for 2 h at RT: donkey anti-rabbit Alexa
Fluor 488 and donkey anti-mouse Alexa Fluor 568 (1:1000,
all Molecular Probes). After three times 10 min washes of
TBS-T, fluorescence signals were detected using the Chem-
iDoc Mp Imaging System (Bio-Rad).
ImageJ (1.44p) and the function “Analyze Gel” was used
for quantitative analysis. The protein band of interest and the
loading control were selected from every loaded sample, andFLA 5.5.0 DTD  JALZ2591_proofthe area under the signal peak was calculated. After manual
background subtraction, the protein band densities were
normalized to b-actin. In addition, the densities of APP-
PS1 lysates were normalized to WT Qlysates and expressed
as relative density to control lysate in %.2.8. Electron microscopy
For ultrastructure analysis, 13-month-old APP-PS1 mice
and WT controls were perfused with 4% paraformaldehyde
and 0.5% glutaraldehyde in 0.1 M PB. Brains were removed,
and 50 mm sagittal sections were cut using a vibratome and
stored in 0.1 M PB with 0.05% sodium azide. Sections with
brain areas of interest were selected and preembedding 3,30-
Diaminobenzidin immunostaining was performed as already
described [23]. As primary antibody, the rabbit anti-DCX
(1:300, Cell Signaling) antibody was used and incubated
over night at RT. After several washes in PBS, sections
were incubated for 3 h with goat anti-rabbit biotinylated
antibody (1:500, Vector). To increase staining signal, sec-
tions were incubated in Vectastain ABC Hrp Kit (Vector)
for 1 h according to manufacturer’s instructions. After three
times 10 min washing in PBS, sections were transferred to
3,30-Diaminobenzidin using the Peroxidase Substrate Kit
(Vector) following manufacturer’s instructions. Sections
were rigorously washed and osmificated by incubating in
1%OsO4 (EMS Q) in 0.1M PB for 1 h. Following threewashes
for 10 min in distilled water, sections were incubated in Ura-
nyl Acetate Replacement Stain- (EMS) for 30 min. Sections
were dehydrated by incubation in an increasing series of
ethanol and transferred to propylenoxide (EMS) before
embedding in araldite durcupan (four component resin,
Sigma) over night in aluminum foil cups at RT. On the
next day, the slices were gently transferred to acetate slides
(100 micron color laser printer film, 5 star office), covered
with small amounts of araldite and coated with a second ac-
etate slide and hardened in an oven at 60C for 3 days. Re-
gions of interest were cut out of the embedded sections,
followed by removing one side of the acetate slide and
glueing on an araldite durcupan block with cyanoacrylate
adhesive (UHU Q). This protocol was performed with small
modifications according to the research group of Jose-Man-
uel Garcia Verdugo [45,46]. After removing the acetate
slides and careful trimming of the samples into a trapezial
shape, semithin sections of 1–1.5 mm were generated using
a Reichert Ultracut S ultra-microtome (Leica). Semithin sec-
tions were transferred to object slides and were stained with
1% Toluidine blue for orientation. After identification of
stained cells, ultrathin sections of 70 nm were directly cut
using a diamond knife (Diatome). Sections were stretched
with chloroform and subsequently collected with 75 mesh
copper grids of 3 mm diameter coated with 0.2% Formvar
solution. Grids were dried and analyzed using a Zeiss Leo
910 electron microscope with an integrated Zeiss 906 TRS Q
USB camera. The utilized software was ImageSP, version
1.2.4.29 from TRS & Sys Prog. 6 April 2018  6:19 pm  ce
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6162.9. Qualitative and quantitative analysis of
immunohistological data
For qualitative image analysis, amyloid plaques in the
cortex, corpus callosum, and hippocampus from 10- to 13-
month-old APP-PS1 animals were analyzed. Quantitative
analysis of mean particle size and percentage area of staining
was performed in 13-month-old APP-PS1 and age-matched
WT littermates. For each animal, four fields of view in the
cortex and hippocampus were photographed as z-stack at
40! magnification using a confocal laser scanning micro-
scope (n 5 3/group). Images were analyzed using ImageJ
software (1.44p). For every image, maximum intensity pro-
jections were generated, and the threshold for each represen-
tative staining was manually set. The number of particles
(bigger than 1 mm2) and the particle areas [mm2] were calcu-
lated for each staining using the ImageJ tool “Analyse parti-
cles”. The total tissue area [in mm2] of each image was
calculated, and the % area (area of stained particles/field
of view) was calculated.
Light microscopic analysis of human brain tissue was
done as follows: images were captured at!100 magnifica-
tion, three from each region of interest: dentate gyrus, ento-
rhinal cortex, and the CA1 and CA2 of the hippocampus,
using a Zeiss Axio Scope A1 microscope with an Infinity
2 camera attached and using the Infinity 2-1C imaging soft-
ware. Image analysis was performed by Image Pro Analyzer,
version 6.3 software blind to disease state. The area of inter-
est was identified, and positive staining was highlighted.
Measurements for area, per area, and integrated optical den-
sity were taken for statistical analysis. All statistical analyses
were done using GraphPad Prism.617
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6352.10. Statistical analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software, version 5-7). Outliers were identified
by Grubb test analysis (https://graphpad.com/quickcalcs/
Grubbs1.cfm). Values between two groups were compared
by the two-tailed unpaired Student’s t-test with or without
Welch’s correction for normally distributed data. Two-way
analysis of variance with Bonferroni post hoc test was per-
formed for learning curve analysis of the MWM data.
P values of P , .0001 (****) and P , .001 (***) were
considered most significant, P , .01 (**) highly significant,
and P , .05 (*) significant. Values were expressed as
mean 6 standard deviation or mean 6 standard error of
the mean.636
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6453. Results
3.1. DCX-immunoreactive cells cluster at amyloid-b
plaques in mouse brains and in human AD brain specimen
By analyzing amyloid plaque pathology in the cortex and
hippocampus of 3-, 10-, and 13-month-old APP-PS1 ani-
mals, we recognized the presence of plaque-associatedFLA 5.5.0 DTD  JALZ2591_proofDCX-immunoreactive cells. These cells appeared with the
onset of amyloid-b plaque deposition. Whereas, 3-months-
old APP-PS1 animals were mostly devoid of amyloid-b pla-
ques, 10- and 13-month-old animals already showed severe
plaque pathology in hippocampal and cortical brain regions
(Fig. 1A and 1B).
Interestingly, we observed increased DCX immunoreac-
tivity clustered at these amyloid deposits (Fig. 1A and 1B).
Three-month-old APP-PS1 animals did barely show any
DCX immunoreactivity outside the neurogenic niches in
cortical or hippocampal brain regions; however, increased
DCX-positive staining was observed in cells surrounding
cortical and hippocampal plaques of 10- and 13-month-old
APP-PS1 animals (Fig. 1A and 1B). To test the specificity
of the DCX antibody, appropriate negative controls were
performed: omitting of primary antibody (Fig. 1C) and stain-
ing with an isotype control antibody (Fig. 1C0) to detect the
level of nonspecific background signal. In addition, we
proved the specificity of the DCX antibody used in this
study, by staining DCX-KO brain tissue. The KO tissue
did not show any staining in the dentate gyrus of the hippo-
campus (Fig. 1C00) or in any other brain region of DCX-KO
animals.
To confirm the DCX protein expression in the APP-PS1
brain, we isolated proteins from the hippocampus and cor-
tex of 13-month-old WT and APP-PS1 animals and per-
formed Western blot analysis. In accordance with the
IHC Qdata, the Western blot analysis showed increased
amounts of DCX protein in the cortex of aged APP-PS1
animals compared with WT (Fig. 1D and 1E). This differ-
ence in DCX protein expression was not detected in hippo-
campal lysates, most likely due to the fact that the adult
hippocampus expresses already high levels of DCX protein
and that the further increase due to plaque-associated
elevation of DCX expression might not be detected by
Western blotting (Fig. 1D and 1E). Alternatively, a reduced
level of hippocampal neurogenesis at this stage might
cover the elevation of plaque-associated DCX protein
levels.
Next, we investigated whether the appearance of DCX
cells clustering around amyloid plaques was specific for
the APP-PS1 mouse model or whether this was a more gen-
eral phenomenon related to amyloid plaque pathologies. In
all additional transgenic AD animal models tested at stages
with advanced amyloid pathology, that is, the APP-Lon/Swe
(11 months old) the APP-SDI (12 months old) and the
Tg2576 (18 months old), DCX-immunoreactive cells were
present at sites of amyloid deposits (Fig. 1F). Moreover,
the analysis of human AD brain samples revealed increased
DCX staining in hippocampus AD samples with plaques
compared with control samples without any amyloid plaques
(Fig. 1G). Furthermore, DCX staining was prominent in hip-
pocampal brain structures of control samples, that is, clini-
cally nondemented, with a detectable amount of plaque
pathology (Fig. 1G). Semi-quantitative analysis revealed
that the percentage area for DCX staining was significantly 6 April 2018  6:19 pm  ce
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Fig. 1. Increased Q22DCX immunoreactivity and protein expression at sites of amyloid deposits in brains of transgenic AD animals and human AD specimen:
DCX-immunoreactive cells (red) were detected at sites of amyloid deposits (Thioflavin S, green) in the hippocampus (A) and cortex (B) of transgenic APP-
PS1 animals with advanced plaque pathology. Three-month-old APP-PS1 animals were devoid of amyloid-b plaques and did barely show DCX-
immunoreactive cells outside the neurogenic niche, whereas 10- and 13-month-old animals, with already severe plaque load, showed clustering of DCX-
positive cells around amyloid plaques. Antibody staining and specificity were tested with appropriate negative controls, as omitting of primary antibody
(C), staining with a rabbit IgG isotype control (C0) and staining of DCX-KO tissue (C00). (D) DCX protein expression was analyzed by Western blot using brain
lysates from 13-month-old APP-PS1 compared with WT mice (n5 4/group). (E) DCX protein was increased in the cortex of APP-PS1 animals compared with
WTanimals, shown here as DCX density relative to control lysate (100%). (F) DCX-immunoreactive cells were detected in brains of various ADmouse models
as the APP-Lon/Swe, APP-SDI and the Tg2576 (DCX in red, Thioflavin S in green). (G) Analysis of human postmortem brain samples revealed increased
immunoreactivity for DCX in the hippocampus of AD specimen and controls with plaque pathology compared with controls without plaques. (H) Percentage
area of staining for DCXwas significantly increased in hippocampal CA1 brain region of human AD specimen compared with controls (scatter plot with mean).
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9083.3. Two different DCX expressing cell types cluster at
amyloid plaques in brains of APP-PS1 mice
We first hypothesized that the plaque-associated DCX
cells might be of neurogenic origin. Therefore, we stained
for markers of cell proliferation (proliferating cell nuclear
antigen), stem and progenitor cells (Nestin, SOX2, PSA-
NCAM), oligodendrocytes (Olig2), astrocytes (GFAP), and
neurons (NeuN). However, none of these markers (except
proliferating cell nuclear antigen) co-localized with the
plaque-associated DCX cells (data not shown, see
Table 1), suggesting that these cells were not of neurogenic
origin. Surprisingly, however, the DCX-positive staining at
sites of amyloid deposition in APP-PS1 animals highly co-
localized with the microglia marker Iba1 (Fig. 2A). Interest-
ingly, in areas with almost no amyloid deposits, microglia
did barely, if at all, express DCX (Fig. 2A, rectangle). How-
ever, microglia directly located at sites of the amyloid pla-
ques were observed as highly immunoreactive for DCX
(Fig. 2A, arrow) to the extent that all plaque-associated
Iba1 cells were DCX positive. We further observed a second
population of DCX-immunoreactive cells, which did not ex-
press Iba1 and hence represent a non-microglia population
(Fig. 2A, arrowhead). To investigate whether some of these
DCX1 cells could be infiltrating macrophages or other pe-
ripheral immune cells, we performed staining with the
pan-leukocyte marker CD45. Remarkably, all amyloid
plaque–associated DCX1 cells clearly co-localized with
CD45 (Fig. 2B, asterisk). One fraction of these cells co-
localized with Iba1 and showed only very faint expression
for CD45 (see Fig. 2B, asterisk), while the other fraction
lacked the expression of Iba1 but was highly positive for
CD45 (Fig. 2B, arrow). Vice versa, all plaque-associated
CD45-positive cells were DCX positive. These data suggest
the presence of two different DCX-expressing cell popula-
tions, one with a microglia identity and one with a hemato-
poietic origin. In the following, we refer to the cells that lack
Iba1 but show high expression of CD45 as CD4511/
DCX1 population; the Iba1 positive but CD45 faintly ex-
pressing DCX-immunoreactive population is termed
Iba11/DCX1.
Next, we performed quantitative analysis of DCX, Iba1,
and CD45 expressions in APP-PS1 brain sections. We
analyzed the percentage area (area of stained particles or
field of view) for each respective staining in cortical and hip-
pocampal brain regions of 13-months-old APP-PS1 animals
and compared age-matched WT littermates. We detected
a significant increase in the percentage area for Iba1
and DCX staining in the cortex of APP-PS1 animalsIn A, B, C, C0, C00, F, DAPI was used as nucleus stain. Unpaired Student’s t-test wi
20 mm (A, B, C, C0, C00, F) and 50 mm (G). Abbreviations: DCX, doublecortin; A
midino-2-phenylindole dihydrochloride hydrate.
FLA 5.5.0 DTD  JALZ2591_proofcompared with WT littermates (Fig. 3A and 3C). DCX
immunoreactivity in the cortex co-localized with Iba11/
CD451 microglia (Fig 3A, insert). Analysis of the hippo-
campus revealed a significant increase in percentage area
of DCX staining (Fig. 3B and 3D). Furthermore, strong
CD4511 cells, negative for Iba1, were detected in the brain
parenchyma as being highly positive for DCX (Fig. 3C,
asterisk).
To analyze the DCX expression at sites of amyloid de-
posits in more detail, we analyzed the ultrastructure of
cortical and hippocampal brain regions from APP-PS1 ani-
mals using immunoelectron microscopy. DCX immunoreac-
tivity was detected at the inner side of the cell membranes in
processes of microglia that were located at sites of amyloid
plaques (Fig. 2C, red arrow). A second population of cells
with very strong DCX staining, but a different morphology
was detected (Fig. 2D). In this population, DCX staining
was localized within the cytoplasm and at the cortical
actin-rich cytoskeleton of these small cells with a round-
shaped nucleus and pseudopod-like structures (Fig. 2D,
red arrow). These cells were identified by their morphology
and CD45 expression (Fig. 2B) as leukocytes.
To summarize, we demonstrated an increased expression
of DCX in brains of AD mouse models with already
advanced plaque pathology and documented the occurrence
of DCX-immunoreactive cells at sites of amyloid-b plaques.
These cells were identified as Iba11 microglia and
CD451 cells with hematopoietic origin. Ultrastructure anal-
ysis revealed intracellular DCX expression in microglia
located at sites of amyloid deposition and in cells with
leukocyte-like morphology.3.4. DCX-immunoreactive cells at sites of amyloid-
plaques are positive for markers of phagocytosis and
contain engulfed plaque material in APP-PS1 mice
Because DCX-immunoreactive cells were observed very
close to the amyloid deposits and co-localized with the mi-
croglia marker Iba1, we investigated whether DCX might
be involved in amyloid plaque clearance. Therefore, we
stained for various markers known to be involved in phago-
cytosis such as the triggering receptor 2 expressed on
myeloid cells (TREM2) and the lysosomal marker CD68.
Indeed, strong co-localization of DCX with TREM2-
positive cells at sites of amyloid-b staining was detected
(Fig. 4A). Also, we observed co-localization of DCX with
CD68-positive microglia (Fig. 4B). In addition to the
described co-localization of DCX with this phagocytosis-
related marker, DCX-immunoreactive cells contained Thio-
flavin S-positivematerial in their cytoplasm (Fig. 4C). More-
over, high resolution images revealed that the DCX-positive
cell cytoplasm reached toward the amyloid plaque depositsth Welch’s correction was performed (H, control n5 7, AD n5 14). Scale:
PP-PS1, APP Swedish PS1 dE9; AD, Alzheimer’s disease; DAPI, 40,60-dia-
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Table 1
List of makers used to characterize the DCX-immunoreactive cells associated with amyloid plaques
Cell type/function Marker Description Colocalization with DCX
Proliferation PCNA Proliferating cell nuclear antigen, DNA clamp for replication 11
Stem and progenitor Nestin Neural stem cells (NSCs) -
Sox2 Neural stem and precursors, astrocytes, TF -
PSA-NCAM Proliferating cells, neural cell adhesion molecule -
Astrocyte GFAP NSCs and astrocytes, intermediate filament (IF) -
Oligodendrocyte Olig2 All oligodendrocytes, TF -
Neuron NeuN Mature neuron, neuronal nuclei protein -
Microglia Iba1 Microglia, inflammation 111
Phagocytosis CD68 Macrophages, phagocytosis marker 1
TREM2 Triggering receptor 2 expressed on myeloid cells 11
Hematopoietic lineage CD45 Leukocyte common antigen 111
B220 CD45 isoform mainly expressed on B-cells -
Ly6G Myeloid differentiation antigen expressed on granulocytes -
CD169 Lectin-like receptor expressed by macrophages/monocytes -
T-cells CD3 T-cell coreceptor used as pan-T-cell marker 11
CD4 Membrane glycoprotein expressed on helper T-cells -
CD8 Cell surface glycoprotein expressed on cytotoxic T-cells 11
Foxp3 Transcriptional regulator expressed on regulatory T-cells -
Abbreviations: DCX, doublecortin; PCNA, proliferation; TF, transcription factor.
NOTE. Detailed IHC characterization was performed using markers for cell proliferation, stem and progenitor cells, astrocytes, oligodendrocytes, neurons,
microglia, phagocytosis, and of the hematopoietic cell lineage. DCX-immunoreactive cells at sites of plaques were negative for markers of neural stem- and
progenitor cells, astrocytes, oligodendrocytes or mature neurons. Most interestingly, DCX immunoreactivity colocalized with markers for cell proliferation
(PCNA), microglia (Iba1), phagocytosis (TREM2, CD68), and with markers for the hematopoietic cell lineage (CD45, CD3, and CD8).
NOTE. Few (1), moderate (11), and high (111).
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1047(Fig. 4D). These data strongly suggest that plaque-
associated DCX cells participate in phagocytosing plaque
material.
3.5. Plaque-associated CD4511/
DCX1 immunoreactive cells are CD31/CD81 T-cells
We further tried to identify the CD4511 hematopoietic
DCX-immunoreactive cell population in the APP-PS1
mouse brain in more detail by using various markers of the
hematopoietic cell lineage (for details see Table 1). The
CD4511/DCX1 cell population in the brain of APP-PS1
did not co-localize with markers of B-cells, granulocytes,
or monocytes (data not shown). However, we found DCX-
immunoreactive CD31 T-cells in the brains of APP-PS1 an-
imals (Fig. 5A). Those T-cells were randomly distributed in
the brains, somewere associated with vessels, but somewere
directly located at sites of amyloid deposition. Because reg-
ulatory T-cells (Foxp31) and CD41 T-cells were described
to enter mouse brains with massive neurodegeneration and
brains of AD animal models [13,47], we tested for CD4
and Foxp3 expression in the DCX1/CD31 T-cell
population. None of these markers were expressed by the
CD4511/DCX 1 cell population. However, the majority
of DCX-immunoreactive cells were positive for the T-cell
marker CD8 (Fig. 5B, insert). Confocal imaging and 3D sur-
face representation of high magnification images revealed
that many of these DCX-immunoreactive CD81 cells
were closely attached to DCX1/Iba11 microglia (Fig. 5C).
In summary, we detected DCX-immunoreactive cells
at sites of amyloid-deposition in APP-PS1 animals. WeFLA 5.5.0 DTD  JALZ2591_proofidentified two subpopulations of these cells: one population
represents an Iba11 microglia population immunoreactive
for DCX, expressing markers for phagocytosis and with
incorporated amyloid deposits. A further subpopulation of
DCX-immunoreactive cells was positive for the T-cell
marker CD3 and was characterized as a CD8-positive
T-cell population most likely entering the brain and highly
interacting with microglia.4. Discussion
We employed a broadly used mouse model for AD, the
APP-PS1 mouse model, which is well described to develop
a variety of human hallmarks for AD pathology. The APP-
PS1 mouse model starts to form amyloid-plaque deposits
from 3–4 months of age [23,48–50] and along disease
progression, it develops reactive astrogliosis [51], micro-
gliosis or microglia activation [52,53], synaptic loss [54],
changes in synaptic long-term potentiation [55], and even
modest neuronal loss adjacent to plaques [56]. These
changes in brain structure and function lead to a decline in
cognitive performance of these mice, tested in several cogni-
tive behavior tasks [55,57]. Indeed, we confirmed impaired
learning and memory function in APP-PS1 mice using
MWM test for spatial learning and memory
(Supplementary Fig. 1). Animals were trained to find a
water-submerged platform over a time period of 5 days,
and the total distance the animals traveled to find the plat-
form was analyzed. APP-PS1 animals significantly traveled
higher distances to reach the platform compared with age- 6 April 2018  6:19 pm  ce
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Fig. 2. DCX in microglia and hematopoietic cells at sites of cortical and hippocampal amyloid plaques in APP-PS1 mice: DCX immunoreactivity strongly
colocalized with the microglia marker Iba1 (A). Microglia close to the amyloid plaques showed DCX expression (arrow), whereas microglia in areas with
no amyloid deposition were barely positive for DCX (rectangle in A). Furthermore, a subpopulation of DCX-immunoreactive cells lacking the expression
of Iba1 was detected (A, triangle). Using the pan-leukocyte marker CD45 for further characterization of the DCX-immunoreactive population revealed two
distinct DCX cell types at sites of amyloid deposition: a DCX1/Iba11/CD451 microglia (asterisk) and a DCX1/Iba12/CD4511 population (B, arrow).
(C) Ultrastructure analysis of DCX-DAB immunostained APP-PS1 brains showed intracellular DCX protein localization in microglia (m) and leukocyte-
like cells (leu) at sites of neuritic cortical and hippocampal amyloid plaques (P). Microglia at sites of an amyloid core and dystrophic neurites (dN), containing
electrodense laminar bodies, showed intracellular DCX expression in their processes and in the cytoplasm along their inner cell membrane (C, red arrows). In
addition, strong polarized DCX expression lining the inner cell membrane was observed in leukocyte-like cells of round shape, with pseudopod-like processes
(D, red arrows). In A, B DAPI was used as nucleus stain. Scale: 50 mm (A, B), 1 mm (C, D) and 500 nm (C, D inserts). Cell Q23bodies and borders were visualized in
blue. Abbreviations: DCX, doublecortin; APP-PS1, APP Swedish PS1 dE9; Abeta; amyloid b; DAB, 3,30-Diaminobenzidin.
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1181matched control animals indicating reduced learning func-
tion (Supplementary Fig. 1A and 1B). Spatial memory anal-
ysis after removal of the platform on day 6 revealed
decreased memory functions in APP-PS1 animals compared
with age-matched controls (Supplementary Fig. 1C). Never-
theless, the APP-PS1mouse has its limitations as a model for
AD. Obviously, spatial learning and memory is only one of
the plethoras of cognitive dysfunctions AD patients are
suffering from, and therefore, data derived from experiments
with APP-PS1 animals should not be overinterpreted. Also,
APP-PS1 mice do not develop NFTs by hyperphosphoryla-FLA 5.5.0 DTD  JALZ2591_prooftion of the tau protein, which is observed in the brains of
many AD patients [37]. Finally, the APP-PS1 model repre-
sents one of the genetic and familial forms of AD and not
the much more frequent sporadic forms.
Here, we identify and characterize DCX-immunoreactive
cells outside the neurogenic niches at sites of amyloid depo-
sition in the brains of transgenic amyloid-plaque mouse
models and in human AD specimen. The plaque-
associated DCX cells were of nonneurogenic origin, as
they lacked the expression of stem or progenitor cell markers
and those of neuronal and glial cells (see Table 1). This 6 April 2018  6:19 pm  ce
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Fig. 3. Semi-quantitative analysis of Iba1, CD45, and DCX expression in APP-PS1 mouse Q24brains: Microglia marker Iba1, pan-leukocyte marker CD45, and
DCX staining in cortical (A) and hippocampal (B) brain regions of 13-month-old APP-PS1 mice. The percentage area (area of stained particles or field of
view) of each respective staining was calculated using ImageJ software. APP-PS1 mice showed a significant increase in percentage area for Iba1 and DCX
staining in the cortex compared with WT littermates (C). DCX expression colocalized with Iba11/CD451microglia (A, insert). Analysis of the hippocampus
FLA 5.5.0 DTD  JALZ2591_proof  6 April 2018  6:19 pm  ce
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1443is essential knowledge, as DCX is generally used as a
marker for young immature neurons and for neurogenesis
[21,22]. Thus, elevated DCX expression in brains with
neurodegeneration outside of the neurogenic niches could
easily be misinterpreted as enhanced neurogenesis. There
were no obvious signs of potential migration of these cells
from the neurogenic niches, instead they were highly
proliferative (data not shown) and clustered at plaques in
the transgenic animal models. This may lead to the
assumption that at least some of these cells were generated
locally. The plaque-associated DCX1 cells were identified
as immune cells, more specifically as Iba11 microglia and
as CD81 T-cells. These two cell types appeared in close
proximity to each other, suggesting that they might interact
and modulate phagocytic and/or immune activities.
DCX is highly expressed in the developing brain, specif-
ically in migrating or differentiating neurons [58,59]. In
the adult organism, its expression is mainly confined to
neuronal precursor cells and young immature neurons in
the neurogenic niches of the dentate gyrus and of the
subventricular zone of the lateral ventricle [21,22]. There
is very little evidence for DCX expression in the adult
uninjured brain in cells outside the neurogenic regions,
and if it appears then, that DCX expression in such areas
is confined to cells of neurogenic origin. For example, in
the piriform cortex, a pool of neurons with an immature
phenotype retains DCX expression in the adult [60], and it
is thought that such immature DCX neurons might provide
the brain circuitry with increased plasticity [61,62].
Interestingly, cortical DCX expression in nonneurogenic
regions is unaffected by age or by neurogenesis-inhibiting
interventions such as radiation [63].
In animal models of stroke, leptomeningeal cells express
DCX, and these cells might contribute to repair processes
[64]. Also, after stroke, the production of DCX cells in the
subventricular zone is increased, and DCX-positive cells
migrate toward the lesion site [65]. Besides immature neu-
rons, GFAP-positive astroglia have been shown to express
DCX after an ischemic lesion [66]. Furthermore, DCX
expression was described in oligodendrocyte precursor cells
of healthy rodent brains [67]. Taking into account that levels
of adult neurogenesis, that is, levels of DCX1 neuronal pro-
genitors, correlate with cognitive behavior in rodent animal
models [68], the nonneurogenic DCX protein expression de-
tected along amyloid pathology has to be carefully inter-
preted. At least, up to now, there is no correlation between
nonneurogenic DCX cells in the brain cognitive outcomes.
Nevertheless, one possible interpretation of this might be a
beneficial process allowing cellular plasticity and involve-
ment in regeneration rather than being detrimental. To
address the question whether nonneurogenic DCX-positiverevealed a significantly increased percentage area of DCX staining in APP-PS1 anim
for Iba1 were detected in the brain parenchyma being highly positive for DCX
(mean6 SD) with or withoutWelch’s correction (n5 3/group) for each staining wa
APP-PS1, APP Swedish PS1 dE9; SD, standard deviation.
FLA 5.5.0 DTD  JALZ2591_proofcells are generally present in rodent models for neurodegen-
erative diseases, we additionally analyzed DCX expression
in a Lewy body dementia mouse model with severe a-synu-
cleinopathy in the brain [34]. We did not observe DCX
expression in these transgenic mice other than in the hippo-
campal neurogenic niche, and there was no co-localization
with microglia marker (Supplementary Fig. 2). Therefore,
it is more likely that the herein described nonneurogenic
DCX expression is specific for amyloid pathology; however,
this would need further investigations. Nevertheless, if so,
this harbors the possibility of the future use of DCX to strat-
ify AD brains in neuropathology.
The microglia fraction of the plaque-associated DCX
cells co-expressed the microglia markers Iba1, CD68,
and TREM2, suggesting that these cells are phagocytic
cells. Indeed, they showed incorporated amyloid deposits
in their cell soma. Interestingly, non–plaque-associated mi-
croglia in the AD brain as well as microglia in wild type
mice did barely show any DCX immunoreactivity. This
might be an explanation for the fact that DCX was so far
never described in microglia of the adult brain. Neverthe-
less, there is evidence that microglia do express DCX un-
der certain circumstances. A RNA sequence database on
embryonic and adult-isolated microglia [69] reveals that
microglia during development do express DCX mRNA at
considerable amounts compared with all genes (FPKM Q
46), but they lose DCX expression during postnatal stages
(http://web.stanford.edu/group/barres_lab/cgi-bin/geneSear
chMariko.py?geneNameIn5DCX).
Also, a transcriptome analysis of amoeboid microglia
versus ramified microglia isolated from the corpus cal-
losum of rat brains revealed expression of DCX in micro-
glia. The DCX gene was within the top 25 highly
expressed genes in amoeboid microglia but was not ex-
pressed in ramified microglia. At the protein level, the
authors demonstrated that amoeboid microglia showed
positive immunoreactivity for DCX [70]. The function
of DCX in developmental or amoeboid microglia is un-
clear, but as DCX is a microtubule-associated protein
involved in neuronal migration [71,72], it might as
well modulate migration and motility of microglia.
Alternatively, DCX might be involved in intracellular
processes such as phagocytosis. Phagocytosis is a key
function of microglia and involves high motility and
plasticity of the intracellular cytoskeleton coordinated by
various receptor complexes on the microglia cell surface
[9]. DCX might play an essential role in cytoskeletal reor-
ganization specifically in microglia associated with the
amyloid-b plaques. Regardless of a putative function of
DCX in this process, the morphology and location, as
well as the expression of the phagocytosis markersals compared withWT (D). Furthermore, strongly CD4511 cells negative
(asterisk in B). DAPI was used as nucleus stain. Unpaired Student’s t-test
s performed (C, D). Scale: 50 mm (A, B). Abbreviations: DCX, doublecortin;
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Fig. 4. DCX1microglia are phagocytotic: Strong colocalization of DCX with the microglia phagocytosis marker TREM2 (A) and with the lysosomal marker
CD68 (B) at sites of amyloid-b deposition. DCX-immunoreactive cells closely attached to the amyloid-plaque had Thioflavin S positive particles incorporated
into their cell soma (C). High-resolution images revealed DCX-positive cell cytoplasm reaching toward amyloid plaques (D, arrow). DAPI was used as nucleus
stain. Scale: 50 mm (A, B), 20 mm (C, D). Abbreviations: DCX, doublecortin; Abeta; amyloid b.
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1582TREM2 and CD68, and the presence of amyloid plaque
material in the DCX cells strongly suggests that they
have phagocytic activity and that they contribute to amy-
loid plaque clearance. The role of TREM2 and of
microglia-mediated phagocytosis in AD pathogenesis is
evident, as human genetic studies showed a higher risk
to develop AD with certain TREM2 variants [73]. Besides
TREM2, the co-localization of the DCX cells with CD68
also points toward a critical role in phagocytosis, as CD68
is expressed in lysosomal vesicles [74,75].
The DCX immunoreactivity was not limited to the mi-
croglia cell population at sites of amyloid plaques. We
identified a specific hematopoietic T-cell population pre-
sent in the brain of APP-PS1 animals, which was positive
for DCX. Assuming that these cells infiltrated the brain
from the periphery, we also analyzed peripheral immune
organs, for example, spleen and bone marrow from adult
mice, and surprisingly found high DCX immunoreactivity
in T-cell–rich areas of this tissue (Supplementary Fig. 3).
We used various markers of the hematopoietic cell lineageFLA 5.5.0 DTD  JALZ2591_proofto characterize these cells in the brain of APP-PS1 animals
and detected mainly CD81 DCX-immunoreactive T-cells
that were in direct contact with microglia. The existence
of two subpopulations of nonneurogenic DCX1 cells is
fascinating and might be explained by their cellular func-
tion: microglia as already discussed previously have to be
highly motile for phagocytosis, and T-cells have to form
and change their cytoskeleton depending on their activity
status [76,77]. Both functions involve cytoskeleton
reorganization and might therefore involve the DCX
protein.
The occurrence of peripheral immune cells, specifically
T-cells, in the brain and their functional role and interaction
with brain resident glial cells is currently discussed, and
increased T-cell homing into the healthy aged brain has
been reported [11,12]. Although the increased occurrence
of T-cells in the brains of patients with autoimmune
diseases such as multiple sclerosis is well documented, the
evidence of T-cells in chronic neurodegenerative disease
such as AD is less [78]. The occurrence of T-cells in the brain 6 April 2018  6:19 pm  ce
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Fig. 5. DCX1/CD81 T-cells in APP-PS1 mouse brains: (A) DCX-immunoreactive cells that lack the microglia marker Iba1 were highly positive for the T-cell
marker CD3. Most interestingly, in the brain, no colocalization with Foxp3 or CD4 was detected (data not shown). (B) The majority of T-cells did express CD8
and were therefore identified as natural killer T-cells present in the brain parenchyma of APP-PS1 animals. These DCX1/CD81 T-cells were often located very
closely to microglia suggesting a strong interaction of these two cell populations (B, insert). High magnification images and 3D surface representation showed
detailed DCX colocalization with CD8 and Iba1-positive cells (C). DAPI was used as nucleus stain. Scale: 50 mm (A, B), 10 mm (C). Abbreviations: DCX,
doublecortin; APP-PS1, APP Swedish PS1 dE9.
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1716was first reported in humanAD postmortem brain biopsies in
1988 [79]. Elevated numbers of T-cells in the brains of am-
yloid plaque mouse models has further been documented in
several transgenic AD mouse models [13]. This, of course,
raises the question whether T-cells might have a modulatory
activity, ameliorating or worsening AD pathology [14].
Whereas, studies on regulatory T-cells (Tregs) report on a
beneficial function of T-cells by slowing down disease pro-
gression and modulating microglia responses to amyloid-b
deposits [80], others report about detrimental effects of
Tregs in AD. For example, while in one study, depletion or
inhibition of Tregs reversed the cognitive deficits in an AD
animal model [47], the genetic ablation of T-, B-, and natural
killer cells in a 5XFAD AD mouse model (Rag-5xfAD)
revealed a twofold increase in amyloid-b plaque pathology
and exacerbated neuroinflammation. Conversely, boneFLA 5.5.0 DTD  JALZ2591_proofmarrow transplantation in these mice again reduced AD pa-
thology [81].
We summarized our findings in a hypothesis model for
T-cell microglia interaction in amyloid plaque-diseased
brains (Fig. 6). It will be essential to uncover the functional
role of the different T-cell subpopulations in the brain along
AD pathology. In particular, research on these cells and
their interactions with CNS resident cells such as micro-
glia, neurons, and others might identify new therapeutic
targets in future. So far, the functional characterization of
these cells is very limited, and their interactions with the
brains resident glial cells are not fully understood. We
confirmed our main findings in several other amyloid pla-
que models and even in human AD brains or brains with
plaque pathology, considering our finding relevant for the
broad AD field. 6 April 2018  6:19 pm  ce
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Fig. 6. Schematic representation of the T-cell microglia interaction showing
DCX1microglia and DCX1/CD81 T-cells associated to amyloid plaques.
With increased amyloid plaque deposition activated microglia cluster at
sites of the amyloid plaques and express the microtubule-associated protein
DCX (Iba11/DCX1, light green). Via blood vessels (orange) DCX1
T-cells (red) were observed to infiltrate the brain parenchyma and closely
attached with brain resident microglia, presumably modulating immune
cell functions. Abbreviation: DCX, doublecortin.
M.S. Unger et al. / Alzheimer’s & Dementia- (2018) 1-1614
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845Acknowledgments
The authors thank the microscopy core facility of SCI-TReCS
(Spinal Cord Injury and Tissue Regeneration Center
Salzburg), Pia Zaunmair, and Stephanie Schwartz for her
support with the animal work. The authors are grateful to
K. Hsiao-Ashe and for S.R. for providing Tg2576 mice.
Furthermore, we thank Fiona Francis for providing DCX-KO
tissue. This work was supported by the FWF Special Research
Program (SFB) F44 (F4413-B23) “Cell Signaling in Chronic
CNS Disorders”, by the FWF Hertha-Firnberg Postdoctoral
programme n T736-B24, by the State Government of Salz-
burg, Austria, (Stiftungsprofessur, and 20204-WISS/80/199-
2014), through funding from the European Union’s Seventh
FrameworkProgram (FP7/2007-2013) under grant agreements
n HEALTH-F2-2011-278850 (INMiND), n HEALTH-F2-
2011-279288 (IDEA), n FP7-REGPOT-316120 (GlowBrain),
by grants of theGerman Research Foundation (RO 2226/13-1)
and by the German Federal Department of Education, Science
and Technology (BMBF #01ED1501 B) within the JPND pro-
gramCrossSeeds to S.R. Tissue for this studywas provided by
the Newcastle Brain Tissue Resource, which is funded in part
by a grant from theUKMedicalResearchCouncil (G0400074)
and by Brains for Dementia research, a joint venture between
Alzheimer’s Society and Alzheimer’s Research UK.1846
1847
1848
1849
1850
1851Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.jalz.2018.02.017.FLA 5.5.0 DTD  JALZ2591_proofRESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources and
meeting abstracts and presentations. Doublecortin
positive cells have been analyzed in AD and in amy-
loid plaque models of AD, however, always in the
context of neurogenic niches. These relevant cita-
tions are appropriately cited.
2. Interpretation: Our findings led to an integrated hy-
pothesis describing two populations of doublecortin
expressing cells associated with plaques, that is, mi-
croglia and CD8 T-cells.
3. Future directions: Need to investigate the role of the
two cell population in plaque pathology.Reference Qs
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